Public Release:  Move over Prozac: New drug offers hope for depression

Journal of Clinical Investigation

An estimated 19 million Americans suffer from depression, and though the symptoms might be recognizable, the brain chemistry that underlies them is incompletely understood. Research suggests that aberrant signaling by a chemical called Brain-Derived Neurotrophic Factor (BDNF) through its receptor TrkB, may contribute to anxiety and depression, and inhibiting this pathway in mice can reduce anxiety and depression-related behaviors. However, translating these findings to clinical studies will require the development of small molecule inhibitors of the BDNF/TrkB pathway that could be used pharmacologically.

In this paper, researchers led by Maxime Cazorla, of Columbia University in New York, and Didier Rognan, of the Université de Strasbourg in France, describe a screen for stable small molecules that could specifically inhibit TrkB action. They identified one they dubbed ANA-12, which had potent behavioral effects when administered to mice that suggest it will have antidepressant and anti-anxiety activity in humans. The researchers are hopeful that this new compound could be used to develop a new class of psychiatric drugs.

###

TITLE:
Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice

AUTHOR CONTACT:
Maxime Cazorla
Columbia University College of Physicians and Surgeons, New York, NY, USA
Phone: 1-212-342-3114; Fax: ; E-mail: mc3195@columbia.edu
View this article at: http://www.jci.org/articles/view/43992?key=6049b2ddb574b08e78c4

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.